Related Experiment Video
Updated: Apr 12, 2026
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Explore the key targets and mechanism of Danggui Buxue decoction against ulcerative colitis: Network pharmacology and
Wen-Juan Liu1, Shan-Bo Ma2, Jia-Xin Li1
1Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, Shaanxi University of Chinese Medicine, Xianyang, 712046, China.
Ethnopharmacological Relevance:
The traditional Chinese herbal formula, Danggui Buxue decoction (DBD), is known for its ability in tonifying Qi and promoting the production of blood. It is extensively utilized in treating menstrual anemia and chronic non-healing ulcers. Whereas the impact of DBD on ulcerative colitis (UC) has not been explored, and its therapeutic mechanisms are not well comprehended.
Aim Of The Study:
The research sought to investigate the impacts and mechanisms of DBD on UC through a blend of network pharmacology and experimental confirmation.
Materials And Methods:
A network pharmacology approach was utilized to predict DBD's potential mechanisms of action on UC, which were then validated through experimental studies using a dextran sulfate sodium (DSS)-induced UC mouse model to assess its protective effects on intestinal injury. Western blot analysis was conducted to examine changes in protein expression within the primary pathway affected by DBD.
Results:
A total of 27 active chemical components, 265 potential targets, and 5867 UC target genes were identified through screening. Of these, 172 common targets were found between DBD and UC. Additionally, 2359 GO biological process items and 157 KEGG signal pathways were identified through analysis. Molecular docking revealed strong binding ability between the main compounds and target proteins. In the DSS-induced UC mouse model, DBD reduced intestinal inflammation and attenuated colonic pathological damage, which is associated with DBD's inhibition of the PI3K/AKT pathway.
Conclusions:
DBD significantly attenuates colonic inflammation and preserves the integrity of the intestinal mucosa. Furthermore, the anti-UC efficacy of DBD is intricately linked to the suppression of the PI3K/AKT pathway.
Related Concept Videos
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...